Q1 Earnings Forecast for ORKA Issued By HC Wainwright

Oruka Therapeutics, Inc. (NASDAQ:ORKA) – Equities researchers at HC Wainwright issued their Q1 2026 EPS estimates for shares of Oruka Therapeutics in a research note issued to investors on Monday, April 28th. HC Wainwright analyst M. Kapoor forecasts that the company will earn ($0.62) per share for the quarter. HC Wainwright currently has a “Buy” rating and a $45.00 target price on the stock. The consensus estimate for Oruka Therapeutics’ current full-year earnings is ($3.41) per share. HC Wainwright also issued estimates for Oruka Therapeutics’ Q2 2026 earnings at ($0.67) EPS, Q3 2026 earnings at ($0.72) EPS, Q4 2026 earnings at ($0.74) EPS and FY2026 earnings at ($2.75) EPS.

A number of other research analysts have also recently weighed in on the company. Wolfe Research assumed coverage on Oruka Therapeutics in a research report on Tuesday, February 4th. They set an “outperform” rating and a $20.00 price objective on the stock. Wedbush reaffirmed an “outperform” rating and set a $40.00 price target on shares of Oruka Therapeutics in a report on Friday, March 7th. Seven analysts have rated the stock with a buy rating and two have issued a strong buy rating to the company’s stock. According to data from MarketBeat, Oruka Therapeutics presently has an average rating of “Buy” and an average price target of $39.86.

Oruka Therapeutics Stock Performance

NASDAQ ORKA opened at $10.09 on Wednesday. The business’s fifty day moving average is $9.99 and its 200 day moving average is $16.37. Oruka Therapeutics has a fifty-two week low of $5.49 and a fifty-two week high of $31.13. The company has a market capitalization of $377.78 million, a PE ratio of -1.61 and a beta of 0.47.

Oruka Therapeutics (NASDAQ:ORKA) last issued its quarterly earnings results on Thursday, March 6th. The company reported ($0.49) earnings per share for the quarter, topping the consensus estimate of ($0.68) by $0.19.

Institutional Inflows and Outflows

A number of institutional investors have recently made changes to their positions in the company. JPMorgan Chase & Co. bought a new stake in Oruka Therapeutics in the 4th quarter worth approximately $54,000. AlphaCentric Advisors LLC purchased a new position in shares of Oruka Therapeutics in the fourth quarter valued at $119,000. China Universal Asset Management Co. Ltd. bought a new stake in Oruka Therapeutics in the fourth quarter worth $144,000. Cannon Global Investment Management LLC bought a new stake in shares of Oruka Therapeutics in the 1st quarter worth about $195,000. Finally, Squarepoint Ops LLC purchased a new position in Oruka Therapeutics in the fourth quarter worth about $236,000. Hedge funds and other institutional investors own 56.44% of the company’s stock.

Insider Buying and Selling

In related news, major shareholder Venrock Healthcare Capital Par purchased 88,794 shares of Oruka Therapeutics stock in a transaction on Friday, February 14th. The shares were bought at an average cost of $11.44 per share, for a total transaction of $1,015,803.36. Following the acquisition, the insider now owns 4,148,428 shares in the company, valued at approximately $47,458,016.32. The trade was a 2.19 % increase in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. In the last three months, insiders have acquired 98,339 shares of company stock valued at $1,128,456. Corporate insiders own 22.67% of the company’s stock.

About Oruka Therapeutics

Oruka Therapeutics, Inc is a biotechnology company, which focuses on developing novel monoclonal antibody therapeutics for PsO and other I&I indications. Its pipeline includes ORKA-001 and ORKA-002. The company is headquartered in Menlo Park, CA.